Results 41 to 50 of about 38,007 (143)

Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing

Frontiers in Immunology
IntroductionNatalizumab (NTZ) is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS) that can be administered intravenously (IV) or subcutaneously (SC).
Alex Agundez-Moreno, Alex Agundez-Moreno, Silvia Presas-Rodríguez, Antonio Manuel González-García, Aina Teniente-Serra, Berta Arcos-Ribas, Berta Arcos-Ribas, Eva Maria Martínez-Caceres, Luis Querol, Lorena Martín-Aguilar, Ángela Vidal-Jordana, Jose E. Meca Lallana, Camila Dos-Santos, Jorge Millan, Gabriel Valero, Antonio Cano, Virginia Casado, Anuncia Boltes-Alandi, Jose Vicente Hervas-Garcia, Luis Brieva, Gary Alvarez, Cristina Ramo-Tello   +21 more
doaj   +1 more source

Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice

Ophthalmology and Therapy, 2023
Introduction Clinical trials in neovascular age-related macular degeneration (nAMD) using anti-vascular endothelial growth factor (ant-VEGF) injections use disease activity (DA) criteria to shorten, maintain or increase the interval between injections ...
Praveen J. Patel, Pablo Villavicencio, Daren Hanumunthadu   +2 more
doaj   +1 more source

Case Report: Extending dosing intervals of biologics in adults severe asthma: a case series

Frontiers in Allergy
BackgroundBiological therapies have improved the control of severe asthma. However, biological therapies are expensive. Therefore, the cost-effective use of these medications after achieving improved disease control warrants consideration.MethodsThis ...
Tomoya Harada, Miyu Nishigami, Hiroyuki Tanaka, Hiroyuki Tanaka, Genki Inui, Hiroki Ishikawa, Hiroki Kohno, Yoshihiro Funaki, Tomohiro Sakamoto, Miki Takata, Ryota Okazaki, Masato Morita, Shin Kitatani, Akira Yamasaki   +13 more
doaj   +1 more source

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients

CPT: Pharmacometrics & Systems Pharmacology, 2023
Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3w dosing remains unknown.
Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini, Laurent Greillier   +5 more
doaj   +1 more source

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam [PDF]

Journal of Antimicrobial Chemotherapy, 2001
A multiple-dose, open-labelled, randomized, two period crossover human volunteer study was performed (i) to describe the pharmacokinetic profile and safety profile of piperacillin and tazobactam (P/T) administered 6.0/0.75 g and 8.0/1.0 g q12h and (ii) to characterize the pharmacodynamic profile of these regimens against a variety of common targeted ...
M K, Kim, D, Xuan, R, Quintiliani, C H, Nightingale, D P, Nicolau   +4 more
openaire   +2 more sources

Predictive performance of gentamicin dosing nomograms

Drug Design, Development and Therapy, 2014
Jieon Lee,1 Seonghae Yoon,1 Donghoon Shin,1 HyeKyung Han,1 Hyungmi An,1,2 Jongtae Lee,1 Kyoung Soo Lim,3 Kyung-Sang Yu,1 Howard Lee11Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul ...
Lee J, Yoon S, Shin D, Han H, An H, Lee J, Lim KS, Yu KS, Lee H   +8 more
doaj  

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma

Experimental Hematology & Oncology
Teclistamab (Tec) and talquetamab (Tal) are bispecific CD3 T-cell engagers targeting B-cell maturation antigen and G protein-coupled receptor, class C, group 5, member D, respectively, and have transformed how we treat relapsed/refractory multiple ...
Callee Brooks, Leslie Mader, Kathryn Kennedy, Phyu Thin Naing, Salyka Sengsayadeth, Bhagirathbhai Dholaria, Adetola Kassim, Sarah Profitt, Muhamed Baljevic   +8 more
doaj   +1 more source

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

BMC Cancer, 2010
Background Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy administration could benefit patients by ...
Silberstein Peter, Rearden Timothy, Mirtsching Barry, Burkes Ronald, Schwartzberg Lee, Yee Lorrin, Inamoto Amy, Lillie Tom   +7 more
doaj   +1 more source

Impact of prednisolone tapering and extended dupilumab dosing intervals on comorbid asthma in patients with chronic rhinosinusitis with nasal polyps

Journal of Allergy and Clinical Immunology: Global
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently coexists with asthma and involves type 2 inflammation. Dupilumab enables prednisolone (PSL) tapering and extended dosing intervals in CRSwNP, but the impact on comorbid asthma is ...
Shunsuke Minagawa, MD, PhD, Masahiro Yoshida, MD, PhD, Daiki Nakashima, MD, Takanori Numata, MD, PhD, Shun Inukai, MD, Tomoya Maruyama, MD, Tetsuya Adachi, MD, PhD, Jun Araya, MD, PhD, Yoshinori Matsuwaki, MD, PhD   +8 more
doaj   +1 more source

Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept

Life
We investigated the factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA).
Akira Machida, Akio Oishi, Junichiro Ikeda, Junko Kurihara, Ai Yoneda, Eiko Tsuiki, Yuki Hirata, Ryuya Murakami, Takashi Kitaoka   +8 more
doaj   +1 more source